Chief Executive Officer @ miRNA therapeutics for cancer One of the fastest moving fields in today's biomedical research concerns small non-coding RNAs in general and microRNA (miRNA) in particular. As insights into the role of these RNA species in health and disease are emerging at high speed, so are the opportunities for developing new diagnostic, prognostic and therapeutic applications. InteRNA Technologies is a Dutch drug discovery and development company engaged in the development of novel breakthrough cancer therapies based on the unique functions of its proprietary miRNAs. Previously undrugable targets now targetable miRNAs provide a natural form of transcriptional interference, repressing protein function. In contrast to small molecules and biologics (like antibodies and siRNA), that hit just one single target, miRNAs can exert a "pleiotropic effect" as 1 miRNA regulates many targets in a network/pathway. As such, miRNAs represent a new class of drugs with a new mode of action. This unique pleiotropic feature of miRNAs allows for targeting of previously undrugable targets, and to increase the sensitivity and/ or decrease the resistance (development) to current drugs on the market. See for more information: www.interna-technologies.com From May 2009 to Present (6 years 8 months) Chief Operating Officer @ InteRNA Technologies aspires to develop intelligent miRNA-based therapeutics to improve cancer therapy effectiveness. To achieve this, we aim to translate our proprietary miRNA discovery technologies and new miRNA molecules into clinically and commercially viable products. From February 2008 to April 2009 (1 year 3 months) Sr. Manager Corporate Finance - Biotech Team @ During the successful year 2007 involved as advisor in IPOs, M&A and stock offerings at Euronext Amstedam/Brussels, private funding of biotech companies and M&A in biotech and energy. From December 2006 to January 2008 (1 year 2 months) VP Corporate & Business Development @ Started as Head Product Development Diagnostics, building up a research team operating between basic R&D and Sales&Marketing and delivering ASR/diagnostic kits ready for sales. I moved to Business Development in 2000. Initiated and have set-up the cancer & genetic diseases FISH-based ASR/diagnostics business. Initially OEM through various licensing partners, later under own brand name. Also involved in out-licensing nucleic acid labeling technology for genomics and protemics applications. From August 1998 to October 2006 (8 years 3 months) Research Scientist (post-doc) @ KWF-NKB Project: The role of integrin alpha6beta4 in hemidesmosome formation, signal transduction and metastasis of squamous cell tumors From November 1996 to July 1998 (1 year 9 months) PhD-student @ Thesis:The biological role of the receptor-like protein tyrosine phosphatase LAR From April 1992 to October 1996 (4 years 7 months)

MBA, Management @ Nyenrode Business University From 2000 to 2001 MSc, Medical Biology @ Radboud Universiteit Nijmegen From 1984 to 1991 Roel Schaapveld is skilled in: Biotechnology, Cancer, Lifesciences, Therapeutics, Treatment, Life Sciences, Diagnostics, Corporate Finance, Patent Applications, Intellectual Property, M&A experience, IPO, Team Building, HR, Business Strategy